Implantation of hiPSC-derived Cardiac-muscle Patches after Myocardial Injury in a Guinea Pig Model
March 18th, 2019
6.9K views
Here we present a protocol for the induction of left ventricular cryoinjury followed by the implantation of a cardiac muscle patch, derived from human iPS-cell cardiomyocytes in a guinea pig model.
Overview
This article presents a protocol for inducing left ventricular cryoinjury in guinea pigs, followed by the implantation of a cardiac muscle patch derived from human iPS-cell cardiomyocytes. The method aims to evaluate the functional consequences of engineered heart tissue implantation in a small animal cryoinfarction model.
Key Study Components
Area of Science
- Cardiovascular research
- Regenerative medicine
- Animal models
Background
- Myocardial infarctions can be induced in a reproducible manner.
- The model allows for stable infarction sizes.
- Understanding heart tissue engineering is crucial for developing therapies.
- Guinea pigs serve as a suitable model for cardiac studies.
Purpose of Study
- To evaluate the effects of engineered heart tissue on cardiac function.
- To assess the viability of using iPS-cell derived cardiomyocytes.
- To improve methods for studying myocardial infarction and recovery.
Methods Used
- Induction of left ventricular cryoinjury in guinea pigs.
- Implantation of cardiac muscle patches.
- Use of echocardiography to assess pre-operative left ventricular function.
- Monitoring of anesthesia and physiological responses during the procedure.
Main Results
- The protocol allows for consistent induction of myocardial infarction.
- Functional assessments demonstrate the impact of the implanted tissue.
- Stable infarction sizes facilitate reproducibility in experiments.
- Results contribute to understanding heart tissue engineering outcomes.
Conclusions
- The method provides a reliable model for studying cardiac repair.
- Engineered heart tissues show potential for therapeutic applications.
- Future studies can build on this protocol to explore further interventions.
Frequently Asked Questions
What is the significance of using guinea pigs in this study?
Guinea pigs are suitable models for cardiac studies due to their physiological similarities to humans.
How does the cryoinjury model work?
The cryoinjury model induces myocardial infarction through controlled freezing, allowing for reproducible injury.
What are iPS-cell derived cardiomyocytes?
iPS-cell derived cardiomyocytes are heart cells generated from induced pluripotent stem cells, used for regenerative therapies.
What role does echocardiography play in this study?
Echocardiography is used to assess left ventricular function before and after the implantation of the cardiac patch.
What are the expected outcomes of this research?
The research aims to improve understanding of cardiac repair mechanisms and the efficacy of engineered tissues.
How can this protocol be applied in future studies?
Future studies can utilize this protocol to test various therapeutic interventions in cardiac repair.
Executive Industry Relevance
This protocol establishes a reproducible preclinical model for evaluating engineered cardiac tissue therapies, addressing the critical need for predictive de-risking in cardiovascular regenerative medicine. By enabling functional assessment of human iPSC-derived cardiomyocyte grafts in vivo, it supports target validation and mechanistic insight for myocardial repair strategies. The model facilitates go/no-go decisions in early discovery by quantifying engraftment, remuscularization, and hemodynamic improvement.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses regarding cardiomyocyte engraftment and functional integration post-injury.
- Operational Value: Provides a standardized cryoinjury model with stable infarct sizes for consistent target engagement assessment.
- Predictive Value: Supports preclinical de-risking by measuring left ventricular ejection fraction and fractional area shortening as quantitative efficacy readouts.
Screening & Assay Development
- Scientific Value: Generates quantifiable histological and functional outputs (e.g., dystrophin+ graft area, Ku80+ human nuclei) to benchmark engineered tissue potency.
- Operational Value: Establishes echocardiography and pressure-volume loop analysis as reproducible assays for longitudinal functional monitoring.
- Translational Value: Delivers disease-relevant structural and functional data to inform dose and timing considerations for patch implantation.
Translational & Preclinical Research
- Scientific Value: Demonstrates partial remuscularization of scar tissue, linking cellular engraftment to tissue-level functional recovery.
- Operational Value: Enables longitudinal evaluation of graft survival and host tissue integration over four weeks post-implantation.
- Risk Mitigation: Identifies procedural risks such as pleural adhesions and ventricular injury during re-do operations, informing surgical refinement.
Pipeline & Workflow Integration
The method fits within the discovery-to-preclinical continuum, supporting hypothesis testing in target validation, assay readiness in screening, and mechanistic de-risking prior to IND-enabling studies.
- Discovery Biology: Tests whether hiPSC-derived engineered heart tissue can structurally and functionally integrate into injured myocardium.
- Screening: Enables standardized assessment of patch engraftment via human-specific Ku80 staining and dystrophin+ remuscularization.
- Analytics: Provides ejection fraction, fractional area shortening, and ventricular dimensions as quantitative endpoints for comparative efficacy.
- Translational Research: Connects cellular engraftment to organ-level function, supporting continuity from cell source to therapeutic outcome.
- Enterprise Reuse: Establishes a reusable platform for evaluating multiple cardiac repair modalities in a disease-relevant guinea pig model.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity by correlating human cardiomyocyte engraftment with improved systolic function.
- Operational Value: Standardizes cryoinjury induction and patch implantation for inter-laboratory reproducibility.
- Strategic Value: Improves capital efficiency by identifying non-viable candidates early through functional thresholds.
- Portfolio Impact: Enables risk-adjusted prioritization of engineered tissue constructs based on remuscularization and hemodynamic improvement.
Implementation Considerations
- Requires expertise in rodent cardiac surgery, echocardiography, and histological processing.
- Dependent on cryoprobe preparation, liquid nitrogen handling, and electrocautery precision.
- Necessitates standardized anesthesia, ventilation, and post-operative care protocols.
- Must account for pleural adhesion formation during re-operative access.
- Limited by guinea pig model scalability for large-scale efficacy screening.
Biopharma FAQs
Why does stable infarct size matter for target validation in cardiac repair studies?
Stable infarct sizes ensure consistent injury severity across animals, enabling reliable assessment of engineered tissue engraftment and functional impact without variability confounding efficacy readouts.
How does isolation of the cryoinjury procedure support discovery pipeline reproducibility?
Isolating the cryoinjury step allows standardized induction of myocardial infarction, reducing procedural variability and improving comparability of functional outcomes across experimental groups.
What quantitative dependent variable measurements enable go/no-go decisions in preclinical cardiac therapy evaluation?
Left ventricular ejection fraction, fractional area shortening, and diastolic diameter provide quantifiable hemodynamic endpoints to determine whether implanted tissue meets functional improvement thresholds for advancement.
Why do replication requirements matter for cross-functional collaboration in cardiac regenerative studies?
Replication requirements ensure that observed benefits of engineered tissue implantation are consistent and reproducible, building confidence among discovery, translational, and clinical teams in therapeutic potential.
What statistical analysis capabilities are required before implementing this model in a discovery workflow?
The model requires capability to analyze longitudinal functional data (e.g., echocardiography trends) and histological quantification (e.g., graft area, human nuclei count) using appropriate statistical tests to assess significance of therapeutic effects.
